Postoperative adjuvant chemotherapy with PVM (Cisplatin + Vindesine + Mitomycin C) and UFT (Uracil + Tegaful) in resected stage I-II NSCLC (non-small cell lung cancer): a randomized clinical trial. West Japan Study Group for lung cancer surgery (WJS
about
Adjuvant chemotherapy for resected early-stage non-small cell lung cancerApoptosis and p53 status predict the efficacy of postoperative administration of UFT in non-small cell lung cancerAdjuvant chemotherapy, with or without postoperative radiotherapy, in operable non-small-cell lung cancer: two meta-analyses of individual patient dataAdjuvant Chemotherapy for the Completely Resected Stage IB Nonsmall Cell Lung Cancer: A Systematic Review and Meta-Analysis.Angiogenesis and the efficacy of postoperative administration of UFT in pathologic stage I non-small cell lung cancer.Meta-analysis of postoperative adjuvant chemotherapy without radiotherapy in early stage non-small cell lung cancerThe future of adjuvant chemotherapy for resected non-small cell lung cancer.Adjuvant chemotherapy for early-stage non-small cell lung cancer: the past, the present and the future.Non-cancer-related mortality after cisplatin-based adjuvant chemotherapy for non-small cell lung cancer: a study-level meta-analysis of 16 randomized trials.Time-to-event endpoints in operable non-small-cell lung cancer randomized clinical trials.Survival prediction of stage I lung adenocarcinomas by expression of 10 genesPostoperative adjuvant therapy for stage IB non-small-cell lung cancer.Predictive value of dihydropyrimidine dehydrogenase expression in tumor tissue, regarding the efficacy of postoperatively administered UFT (Tegafur + Uracil) in patients with p-stage I nonsmall-cell lung cancer.Better estimates of survival for patients considering adjuvant chemotherapy after surgery for early non-small-cell lung cancer.Relationship of tumor size to survival in patients with pT2N0 lung cancer.
P2860
Q24187439-272D5300-0E02-49E1-9FE6-3A840AB6DE3EQ28346767-34F46C3F-EA1C-4D0B-9D05-018F41EC37E0Q33546241-3BC2B20E-7EAA-4394-8745-F08447456882Q34479081-38DBA075-E998-4BA2-BD62-55E5F38CAF21Q35741367-11DD5E05-6BDB-4BFC-A1ED-F4036E192A3BQ35934898-B09046E3-6E99-40A7-A4C1-33AF373AA8E1Q36066186-3746ED3A-AAFF-4EE4-8FE0-72D9A1C3B7A0Q36521844-411D6E66-E4AE-4E58-BE1C-67BF97EB7D53Q38118178-DDA4E75D-5E95-4CA6-955F-1B167A91B857Q39034554-6407E240-BD56-480B-BDBD-8B4F4A324AFDQ42585784-E87951BD-4FCC-4563-A7C7-F639F1D3A887Q43681814-07471A20-6262-40D0-851D-224F07802EB0Q44159643-4E06C4D0-E2E1-4A03-AF40-17761CCB8ECEQ45344139-B944BC80-D36B-4E0E-B2F7-F627E19A89D5Q47352301-0C52777D-7DD2-4A0C-9D53-434E28968C76
P2860
Postoperative adjuvant chemotherapy with PVM (Cisplatin + Vindesine + Mitomycin C) and UFT (Uracil + Tegaful) in resected stage I-II NSCLC (non-small cell lung cancer): a randomized clinical trial. West Japan Study Group for lung cancer surgery (WJS
description
1999 nî lūn-bûn
@nan
1999年の論文
@ja
1999年学术文章
@wuu
1999年学术文章
@zh
1999年学术文章
@zh-cn
1999年学术文章
@zh-hans
1999年学术文章
@zh-my
1999年学术文章
@zh-sg
1999年學術文章
@yue
1999年學術文章
@zh-hant
name
Postoperative adjuvant chemoth ...... p for lung cancer surgery (WJS
@en
Postoperative adjuvant chemotherapy with PVM
@nl
type
label
Postoperative adjuvant chemoth ...... p for lung cancer surgery (WJS
@en
Postoperative adjuvant chemotherapy with PVM
@nl
prefLabel
Postoperative adjuvant chemoth ...... p for lung cancer surgery (WJS
@en
Postoperative adjuvant chemotherapy with PVM
@nl
P2093
P1476
Postoperative adjuvant chemoth ...... p for lung cancer surgery (WJS
@en
P2093
P304
P356
10.1016/S1010-7940(99)00031-7
P577
1999-04-01T00:00:00Z